Alternatively, it is possible that CMV-induced immunoregulatory pathways, including interleukin-10 (IL-10) secretion, may dampen local inflammation in areas of CMV reactivation, thereby reducing the risk of autoimmunity responsible for the neurological symptoms of LC [96]. The gene discussed is IL10; the disease is laryngotracheoesophageal cleft.